{"id":"W1821979477","doi":"10.1371/journal.pone.0134703","title":"First-In-Human, Phase 1, Randomized, Dose-Escalation Trial with Recombinant Anti–IL-20 Monoclonal Antibody in Patients with Psoriasis","year":2015,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Astellas Pharma; Novo Nordisk; York University; Wake Forest University; Amgen","keywords":"Tolerability; Medicine; Placebo; Psoriasis Area and Severity Index; Pharmacodynamics; Pharmacokinetics; Internal medicine; Psoriasis; Adverse effect; Randomized controlled trial; Gastroenterology; Pharmacology; Immunology; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002857875,0.001924236,0.002955416,0.0004191042,0.000527442,0.001067582,0.001054215,0.001310517,0.005566807],"category_scores_gemma":[0.001572058,0.0007697924,0.001154077,0.000371008,0.001136652,0.001025442,0.0003838168,0.003794324,0.001076997],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008750707,"about_ca_system_score_gemma":0.001679049,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00051049,"about_ca_topic_score_gemma":0.001565014,"domain_scores_codex":[0.9992092,0.0004365681,0.00003682102,0.0001298287,0.00007225435,0.0001152887],"domain_scores_gemma":[0.9990076,0.0002214675,0.0002608927,0.00008748169,0.00006351373,0.0003590692],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9250172,0.03227906,0.001350652,0.0005927218,0.000533103,0.00006777399,0.00009650713,0.0005766858,0.01080865,0.0001199366,0.001797405,0.02676035],"study_design_scores_gemma":[0.8909698,0.1055687,0.001547519,0.00001463897,0.0001536268,0.00006070336,0.000008974504,0.0002998672,0.0006404635,0.0000834754,0.0006424838,0.000009857672],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9863159,0.004124243,0.0007487421,0.0007986149,0.0003637816,0.004842357,0.0009796603,0.0001627323,0.00166391],"genre_scores_gemma":[0.9826955,0.00245765,0.003000895,0.001676763,0.0006967233,0.005379211,0.001435205,0.00004024474,0.002617866],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005566807,"threshold_uncertainty_score":0.01862282,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03412512852354042,"score_gpt":0.2550022592565215,"score_spread":0.2208771307329811,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}